Form 4: Eileen Murray receives 167 DCUs under Broadridge Omnibus Plan
Rhea-AI Filing Summary
Broadridge Financial Solutions director Eileen K. Murray received 167 Deferred Stock Units (DCUs) on 09/17/2025 as reported on a Form 4. The DCUs were granted under Broadridge's 2018 Omnibus Award Plan in connection with her deferral of cash compensation under the Director Deferred Compensation Program. The units vest in full upon grant and will be settled into shares of Broadridge common stock beginning when the director separates from service. Following the grant, Ms. Murray is reported to beneficially own 3,698 shares of common stock. The Form 4 was signed by Maria Allen by power of attorney on 09/19/2025.
Positive
- Grant of 167 Deferred Stock Units that vest in full upon grant, providing immediate equity alignment for the director
- DCUs will settle into shares upon the director's separation from service, preserving compensation value for the reporting person
Negative
- None.
Insights
TL;DR: Routine director compensation deferral; units vest immediately and convert to stock at separation.
The filing documents a standard director compensation arrangement where cash fees were deferred into 167 Deferred Stock Units granted under the 2018 Omnibus Award Plan. Immediate vesting on grant reduces forfeiture risk for the director and aligns eventual payout with equity. Settlement is contingent on separation from service, reflecting a typical deferred equity structure for non-employee directors. No cash purchase, exercise price, or derivative instruments are reported. The disclosure is procedural and consistent with established director compensation practices.
TL;DR: Non-material insider acquisition reported; transaction increases beneficial ownership by 167 shares-equivalent units.
The Form 4 reports acquisition code 'A' for 167 Deferred Stock Units at a reported price of $0.0000, indicating these units were granted as deferred compensation rather than purchased. The filing shows total beneficial ownership of 3,698 shares after the grant. There are no derivative securities or disposals disclosed. From a market-impact perspective, this is a routine insider compensation disclosure with limited material effect on share count or control based solely on the information provided.